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Objectives: The aim of our study is to calculate the annual health insurance 
treatment cost of anxiety in Hungary. MethOds: The data derive from the finan-
cial database of the Hungarian National Health Insurance Fund Administration 
(NHIFA), the only health care financing agency in Hungary. We analyzed the 
health insurance treatment cost and the number of patients for the year 2010. 
The following cost categories were included into the study: out-patient care, in-
patient care, CT-MRI, PET, home care, transportation, general practitioner, drugs 
and medical devices. Results: The Hungarian National Health Insurance Fund 
Administration spent 13.535 billion Hungarian Forint (HUF) (65.026 million USD) 
for the treatment of anxiety patients. The annual average expenditure per patient 
was 13323 HUF (64 USD) while the average expenditure per one inhabitant was 1352 
HUF (6.5 USD). Major cost drivers were general practitioners of primary care (43.8 
% of total health insurance costs), pharmaceuticals (32.2 %) and outpatient care 
(12.4 %). The number of patients with anxiety disease was 1014 per 100000 popula-
tions. We found the highest patient number in general practitioners of primary care 
(1015938 patients), pharmaceuticals (774096 patients) and outpatient care (521760 
patients). cOnclusiOns: Anxiety represents a significant burden for the health 
insurance system. General practitioners of primary care and pharmaceutical reim-
bursement are the major cost drivers for anxiety disease in Hungary.
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Objectives: Resulting from the scarcity of literature on dementia in China, a 
Delphi panel was used to obtain information on disease management, resource 
utilisation and associated costs for patients with moderate or severe dementia in 
China. The panel results were used as input data for a health economic model com-
paring different alternative strategies for treatment of dementia. MethOds: The 
Delphi panel method was used to leverage expertise of physicians involved in the 
treatment of dementia (Round-1 interviews with eight interviewees) and hospital 
administrators (Round-2 interviews with two interviewees). Final Delphi meeting 
gathered six experts from previous interviewees to reach a consensus. Round-1 
interviews collected information of establishing a diagnosis for dementia, dementia 
disease management and the distribution of patients by severity, dependence and 
aggressiveness. Round-2 interviews were based on results of Round-1 interviews 
to collect data on relevant costs. Interviews were done individually without shar-
ing information from other interviewees. Results from two rounds were integrated 
and shared in the final Delphi discussion. A consensus was reached to obtain the 
final value or range of values of interest. Results: Distribution of independent/
non-aggressive, independent/aggressive, dependent/non-aggressive, and depend-
ent/aggressive moderate dementia patients was 70%, 15%, 10% and 5% at time 
of first diagnosis . Unit costs and resources utilisation, collected for each health 
state for a cycle of 6-months, showed that severe dependent/aggressive dementia 
patients required the most time from caregivers (15 hours/day). Moderate depend-
ent/aggressive patients had the highest probability (90%) to be hospitalised. The 
average stay of hospitalisation was two months. Moderate and severe patients had 
the same probability of nursing home utilisation (0%, 20%, 80% and 20% for each 
health state). cOnclusiOns: Delphi panel may be a useful approach to collect 
data for diseases when they are not published in the literature or when automated 
health care databases are not available or accessible.
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Objectives: To review studies that investigated the costs and resource use of 
managing major depressive disorder (MDD) in China. MethOds: A structured 
literature review on published articles in both English and Mandarin languages 
was conducted. Literature search was conducted using PubMed, Cochrane, Wan 
Fang, and VIP databases. Articles published between 2000 to 2013 were selected. The 
inclusion criteria included studies conducted in China, and studies that reported 
direct and indirect costs in MDD management, including factors that affected these 
costs, as well as resources used in managing MDD. Four reviewers (two for each 
language) independently selected and reviewed the articles. Direct cost included 
costs of MDD treatment (e.g. medication, investigation, hospitalisation, nursing 
care…etc.); whereas indirect costs included caregiver cost, productivity loss, and 
mortality (suicide). Results: A total of 24 articles in Mandarin and English were 
selected and reviewed. Based on the review, direct cost for MDD reported ranged 
from RMB 1,000 to RMB 6,000, whereas indirect cost reported ranged from RMB 
2,000 to RMB 51,000. Loss of productivity, when evaluated, accounted for more than 
75% of indirect costs. Serotonin norepinephrine reuptake inhibitor (SNRI) incurred 
the highest direct medical cost compared to selective serotonin reuptake inhibitor 
(SSRI), followed by tricyclic antidepressants (TCA). The treatment costs for MDD 
had increased gradually over the years. Some of the common factors affecting the 
cost of MDD management included treatment duration, payment methods, types 
of drug prescribed, comorbidity, disease severity and marital status. Studies had 
shown that most patients first seek treatment in general clinic or hospitals (76%) 
consisted of the direct economic burden of this disease. cOnclusiOns: Serious 
economic burden has been caused by schizophrenia and increased sharply in China. 
Indirect cost of schizophrenia is largely more than its direct cost.
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Objectives: Ziprasidone is increasingly used for the treatment of schizophrenia 
and bipolar disorder. The purpose of this study is to compare health care costs 
and utilization associated with use of ziprasidone and olanzapine. MethOds: 
Schizophrenia and bipolar disorder patients who initiated use of ziprasidone or 
olanzapine between 01/2007 and 12/2010 were identified in the IMS LifeLink™ 
Health Plan Claims Database. Claims were summarized into treatment episodes, 
and one-year costs and utilization after the initiation of episodes were analyzed. 
OLS regressions, general liner models, and two-part models were used to com-
pare various types of costs associated with the use of ziprasidone and olanzapine. 
Logistic regressions, Poisson regressions, and Hurdle models were used to com-
pare the numbers of emergency room visits and hospitalizations associated with 
each drug. Lastly, we used various statistical methods to test the sensitivity of our 
estimates. Results: We identified 7,138 (46.93%) ziprasidone episodes and 8,072 
(53.07%) olanzapine episodes, and found that patients using ziprasidone were signif-
icantly younger (41.50 vs. 45.38) and were significantly less likely to be male (29.81% 
vs. 44.21%). At baseline, ziprasidone group and olanzapine group differed in total 
costs and several other components of costs. Benchmark analyses show that use of 
ziprasidone, when compared to olanzapine, was associated with significantly higher 
medication costs ($232, p< 0.01) and outpatient costs ($501, p< 0.05), but decreased 
ER costs (-$73, p< 0.05). Ziprasidone was also associated with significantly fewer 
ER visits (0.266, p< 0.001) and hospitalizations (1.117, p< 0.001). Sensitivity analyses 
suggest these results were robust. cOnclusiOns: While ziprasidone is associated 
with higher medication costs and outpatient costs, it reduces patients’ utilization 
of ER and inpatient services.
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Objectives: The aim of our study is to calculate the annual health insurance 
treatment cost of Alzheimer dementia disease in Hungary. MethOds: The data 
derive from the financial database of the Hungarian National Health Insurance 
Fund Administration (NHIFA), the only health care financing agency in Hungary. We 
analyzed the health insurance treatment cost and the number of patients for the 
year 2010. The following cost categories were included into the study: out-patient 
care, in-patient care, CT-MRI, PET, home care, transportation, general practitioner, 
drugs and medical devices. Results: The Hungarian National Health Insurance 
Fund Administration spent 4.426 billion Hungarian Forint (HUF) (21.266 million 
USD) for the treatment of Alzheimer patients. The annual average expenditure per 
patient was 72881 HUF (350 USD) while the average expenditure per one inhab-
itant was 442 HUF (2.1 USD). Major cost drivers were acute inpatient care (45.8 
% of total health insurance costs), chronic inpatient care (28.1 %) and pharma-
ceuticals (10.4 %). The number of patients with Alzheimer disease was 60.6 per 
100000 populations. We found the highest patient number in outpatient care budget 
(60735 patients), general practitioners (60234 patients) and pharmaceuticals (37724 
patients). cOnclusiOns: Alzheimer dementia disease represents a significant bur-
den for the health insurance system. Hospital care (both acute and chronic) is the 
major cost driver for Alzheimer disease in Hungary.
PMH16
to study tHe treatMent Pattern and cost of Illness In BIPolar 
dIsorder PatIents In tertIary care HosPItal In soutH IndIa
Sumangala A.1, Thunga G.2
1Manipal university, Udupi, India, 2Manipal College of Pharmaceutical Sciences, Manipal 
University, Manipal, India
Objectives: To study the treatment pattern and cost of illness in bipolar disorder 
patients in tertiary care hospital in South India. MethOds: A retrospective study 
was conducted in a tertiary care teaching hospital of South India. Data were col-
lected retrospectively from medical record section from 2012 to 2013 in suitable 
designed case record form. Data were analysed by using SPSS 20.0. Results: Total 
of 100 cases of bipolar disorder was followed during the study period. Among them 
66 were males and 34 were females. The mean age of the study population was 
found to be 46.2+13.3 years. Among the social history 13 people were alcoholic and 
60% of the study population had a family history of known psychiatric disorder. 
The mean duration of illness of the study population was found to be21.8+9.8years. 
Among the study population 34 patients were diagnosed with mania and 46 patients 
diagnosed with depression. Mood examination revealed that 38 patients were happy 
followed by 22 patients were irritable. Affective examinations showed maximum 
were euphoric. Insight examination showed Grade 1 predominance. The different 
treatment pattern revealed that all of them were prescribed with mood stabilizer 
followed by anti-psychotic (93) and hypnotics (86). The average hospitalization cost 
of the patient was found to be 7477.83 + 5989.67 Rupees with median hospital stay 
of 7(5) days. The average treatment cost constitutes total 50% of the hospitalization 
cost. cOnclusiOns: Mood stabilizers and anti-psychotics were the main treatment 
strategies among the bipolar patients and drug cost consumes 50% of the total cost 
of hospitalization. Pharmacoeconomic studies plays important role in estimating 
the total health care burden in bipolar disorders.
